Is teritolumab a targeted drug? How is it different from traditional medicine?

Teritusumab (Teclistamab) is a targeted drug that belongs to a class of bispecific T-cell Engager (BiTE). It is mainly used to treat relapsed or refractory multiple myeloma. It targets both B cell maturation antigen (BCMA) and T cell surface antigen pan>CD3 achieves T cell-mediated killing of tumor cells by guiding T cells to tumor cells. This mechanism makes it show good therapeutic prospects in some patients for whom traditional treatments are ineffective.

Compared with traditional chemotherapy drugs, teritusumab is highly targeted. Traditional chemotherapy usually works by killing rapidly dividing cells. Therefore, it not only kills cancer cells, but also affects normal cells, such as bone marrow cells, digestive tract epithelium and hair follicle cells, which can easily cause side effects such as hair loss, nausea, and immune suppression. Teritusumab reduces damage to healthy cells to a certain extent by accurately identifying specific targets, thereby improving the selectivity and tolerability of treatment.

However, despite its higher targeting, teritusumab may also cause some unique adverse reactions during its treatment. For example, because it activates T cells, it can lead to cytokine release syndrome (CRS) and immune-related neurological adverse reactions (ICANS). These side effects require close monitoring and management under professional medical care, especially during the initial treatment phase.

Overall, teritusumab represents a novel targeted immunotherapy strategy that is particularly suitable for patients after failure of conventional treatments. Its emergence provides new hope for the treatment of multiple myeloma, but it also places higher management requirements on medical institutions. Before receiving treatment with this drug, patients should learn more about its mechanism, potential risks and required monitoring measures, and communicate closely with their doctor to develop an individualized treatment plan.

Reference materials:https://www.tecvayli.com/